Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
Medpage Today on MSN11h
'Popular' Cancer Misinformation; Menthol Smokes Riskier; Farmers vs PesticidesPatients with metastatic cancer had better quality of life, clinical outcomes, and sense of well-being when they regularly ...
Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Bailey Hutchins, a registered nurse and social media influencer, tragically passed away at the age of 26, following a ...
Gladstone Institutional Advisory LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.9% in the fourth ...
Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...
The 33-year-old was experiencing strange symptoms including extreme fatigue, loss of appetite and stomach issues ...
Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) have received a consensus rating of “Buy” from the thirteen ratings firms that are covering the firm, MarketBeat reports. One analyst ...
American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Case-Based Session: Management of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback